New China Approvals Include Amgen, Sanofi, Hengrui Drugs, Innovent Biosimilar
Executive Summary
Several high-profile products including Dupixent gain approvals in China.
You may also be interested in...
Sanofi Showcases Long-Term Benefits Of Dupixent For Severe Asthma
While many analysts have been focusing on the growth potential of Regeneron-partnered Dupixent in atopic dermatitis, the French giant has been highlighting the biologic's benefits for asthma with three-year data presented at the ERS meeting.
No Looking Back For Sanofi In R&D Turnaround Quest
Sanofi's R&D operation has shaken the dust of diabetes off its feet with an update on its ambitious pipeline plans at an R&D day event.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.